Intravenous Administration of Docetaxel to Cats with Cancer

Abstract

Background: The safety of IV administration of docetaxel to cats with cancer has not been reported. Objectives: Document adverse effects of IV administration of docetaxel to cats. Animals: Twenty-one client-owned cats with any confirmed malignancy. Methods: Cats received up to 5 docetaxel treatments, administered IV every 3 weeks. The initial dosage was 1.0 mg/kg, and dosages were increased by increments of 0.25 mg/kg in cohorts of 3 cats. Adverse events were determined by a CBC at days 7 and 21, serum chemistry and urine specific gravity at day 21, and medical histories provided by the owners.Results: Cats received docetaxel dosages ranging from 1.0 to 2.5 mg/kg, for a median of 2 treatments. Dose-limiting toxicoses included fever, neutropenia, and vomiting, seen in 2 of the 4 cats treated at 2.5 mg/kg. Hypersensitivity reactions were infrequent (4 of the 21 cats) and mild. The maximum tolerated dosage was 2.25 mg/kg.Conclusions and Clinical Importance: Docetaxel can be administered IV to cats with a low incidence of adverse effects.

Exploration of paclitaxel (Taxol) as a treatment for malignant tumors in cats: a descriptive case series

“…Observed adverse side effects included fever, neutropenia and vomiting. 6 Another study assessed IV docetaxel as a treatment for metastatic mammary carcinoma in cats, which demonstrated a response rate of 84.6%. 7 Both paclitaxel and docetaxel have been tolerated by canine cancer patients, with hematopoietic (neutropenia) and gastrointestinal reactions being the dose-limiting adverse effects, respectively.…”